Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RHB-104 in Crohn's Disease
NCT01951326Phase 3Completed
- Sponsor
- RedHill Biopharma
- Start
- Sep 2013
- Primary completion
- May 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing RHB-104 with Placebo (2 arms). Primary endpoint: Remission at Week 26. Started Sep 2013; status: completed.
02
Drugs
RHB-104
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01951326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01951326.